文献速递浆细胞疾病

伴临床特征进展与多发性骨髓瘤后续生存更差相关

Progression with clinical features is associated with worse subsequent survival in multiple myeloma.
PubMed 文献 · Am J Hematol · 2019-02-06

该回顾性队列研究纳入252例首次复发多发性骨髓瘤患者,按复发进展模式分为生化进展(BP)134例、临床进展无髓外病变(CP/EM-)87例和临床进展伴髓外病变(CP/EM+)31例。中位随访26个月,三组中位总生存分别为50、19和10个月(P<0.001);多因素分析显示进展模式是独立预后因素。

要点

  • 首次复发时伴临床特征进展或髓外病变者后续生存显著更差。
  • CP/EM+组诊断至首次复发时间及异常核型比例均高于其他两组。
  • 进展模式是多因素分析中独立于年龄的总生存预后因素。

核心结论

  • 在当前时代进展模式是重要预后因素,复发时伴终末器官损害或髓外病变者后续生存极差。
  • 作者认为复发多发性骨髓瘤临床试验应报告基线进展模式以确保研究组间平衡。

研究设计与样本

  • 回顾性队列研究,纳入252例经历首次复发(时间点T0)的多发性骨髓瘤患者。
  • 按进展模式分为三组:BP组134例(53%)、CP/EM-组87例(35%)、CP/EM+组31例(12%)。

主要发现

  • 诊断至T0的中位时间:CP/EM+组13个月 vs CP/EM-组25个月 vs BP组25个月(P<0.001)。
  • 诊断时异常中期细胞遗传学的发生率:CP/EM+组46% vs CP/EM-组18% vs BP组11%(P<0.001)。
  • 自T0起中位随访26个月,中位总生存:BP组50个月、CP/EM-组19个月、CP/EM+组10个月(P<0.001)。
  • 多因素分析中进展模式为总生存的显著预后因素:CP/EM- vs BP的HR为3.6,CP/EM+ vs BP的HR为8.7,CP/EM+ vs CP/EM-的HR为2.42(所有比较P<0.001),年龄(T0时)亦为显著因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Response rate and survival in multiple myeloma (MM) has improved in the era of proteasome inhibitors and immunomodulatory drugs. However, most patients eventually relapse with biochemical progression (BP) alone or with clinical features of end-organ damage (CP: clinical progression), without or without extramedullary (EM) disease. We conducted a retrospective cohort study of 252 patients with MM experiencing first relapse (time, T0 ) to evaluate survival following CP with and without EM as a function of BP. Patients were divided into three groups: BP (n = 134; 53%), CP/EM- (n = 87; 35%) and CP/EM+ (n = 31; 12%). The median time from diagnosis to T0 was significantly shorter in CP/EM+ compared to CP/EM- and BP groups (13 vs 25 vs 25 months; P < 0.001). The incidence of abnormal metaphase cytogenetics at diagnosis was significantly higher in CP/EM+ compared to CP/EM- and BP groups (46% vs 18% vs 11% respectively; P < 0.001). At a median follow-up of 26 months from T0 , median overall survival was 50, 19 and 10 months for BP, CP/EM- and CP/EM+ groups, respectively (P < 0.001). On multivariable analysis, pattern of progression was a significant prognostic factor for OS (HR for CP/EM- vs BP: 3.6; CP/EM+ vs BP: 8.7 and CP/EM+ vs CP/EM-: 2.42; P < 0.001 for all comparisons), along with age at T0 . In conclusion, progression pattern is an important prognostic factor in the current era, with subsequent survival being dismal in patients with end-organ damage or EM disease at relapse. Clinical trials in relapsed MM should consider reporting patterns of progression at baseline to ensure balance between study arms.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Chakraborty R, Liu HD, Rybicki L, et al. Progression with clinical features is associated with worse subsequent survival in multiple myeloma. Am J Hematol. 2019. PMID: 30663805. doi:10.1002/ajh.25415

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。